HOWL Werewolf Therapeutics2.83+0.78 (+38.1%)
After Hours Decliner
HOWL Werewolf Therapeutics5.16+0.27+5.5%
After Hours:5.00-0.16 (-3.1%)
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Globe NewswireThu, 23-May 5:00 PM
HOWL Werewolf Therapeutics6.58+1.85 (+39.1%)